regulation · private-vs-medical
What changed for medical cannabis under the Cannabis for Private Purposes Act 2024
Last reviewed · Reviewed by Docto24 editorial
The Cannabis for Private Purposes Act decriminalised adult private cultivation and use — but the medical pathway is a separate framework that did not change. Here is the practical distinction.
The Cannabis for Private Purposes Act, signed into law in 2024, decriminalised adult private possession, cultivation, and use of cannabis in South Africa. Patients sometimes assume this means they can grow their own cannabis for medical use — and skip the SAHPRA Section 21 application, the doctor consultation, the pharmacy chain. That assumption is wrong, and the misunderstanding has practical consequences.
Two distinct legal frameworks
South African cannabis law now has two largely separate regulatory tracks. The **private-use track** under the Cannabis for Private Purposes Act covers what an adult may possess, grow, and use privately on private property — quantities, locations, and conduct rules apply, but commercial sale and public use remain restricted. This Act does not concern itself with medical evidence, dose, formulation, drug interactions, or quality control.
The **medical track** under the Medicines and Related Substances Act 101 of 1965 (specifically Section 21) governs the prescribing, dispensing, and quality oversight of cannabis as medicine. This is the framework Docto24 operates within — HPCSA-registered doctors, SAHPRA-authorised products, licensed pharmacy dispensing, batch-tested formulations.
Why your home-grown cannabis is not "medical"
Three things the medical pathway provides that home cultivation cannot:
**Dose certainty** — pharmaceutical-grade Section 21 products specify the exact cannabinoid content (mg of THC, mg of CBD per millilitre or per dose). Home-grown cannabis varies dramatically batch-to-batch and plant-to-plant; you do not know what dose you took.
**Quality control** — Section 21 products are batch-tested for cannabinoid content, microbial contamination, residual solvents, pesticides, and heavy metals. Home-grown cannabis carries unknown contamination risk that matters more for patients with compromised immunity, lung disease, or comorbid conditions.
**Doctor + regulator oversight** — your Section 21 prescription is part of a clinical record. Drug interactions are checked. Dose changes are monitored. Adverse events are reportable. None of that exists in private-use cannabis.
When the private-use Act does help patients
For patients pursuing Section 21 medical cannabis, the private-use Act primarily reduces stigma and legal risk around possession of small amounts in transit between pharmacy and home — these were grey areas before and are now clearer. It also widens the cultural acceptance environment within which doctors can have honest conversations about cannabinoid therapy.
It does not, however, allow doctors to prescribe home-grown product, allow pharmacies to dispense without authorisation, or reduce the SAHPRA application requirement for any medical purpose. Those remain governed by the Medicines Act framework, and that framework has not changed under the new private-use legislation.
Practical takeaway
If you have a clinical indication that may benefit from cannabinoid therapy, the medical pathway exists for a reason — clinical assessment, drug-interaction review, and quality-controlled product. The private-use Act gives you legal cover for general possession; it does not substitute for medical care. Patients who try to combine the two — using home-grown product as if it were prescribed medicine — generally end up either under-dosed (no benefit), over-dosed (side effects), or experiencing interactions with their existing medications that no one has flagged.
Glossary terms in this article
Researching whether the Section 21 cannabis pathway is right for you? The eligibility assessment takes around five minutes.
START ELIGIBILITY ASSESSMENT